帕博利珠单抗治疗晚期前列腺腺癌:KEYNOTE-028研究结果
KEYNOTE-028是一项非随机Ib期试验,评估帕博利珠单抗在晚期实体瘤中的疗效。前列腺腺癌队列纳入23例PD-L1阳性(≥1%)且标准治疗失败的患者,每2周接受帕博利珠单抗10 mg/kg治疗。客观缓解率为17.4%(95%CI 5.0%-38.8%),中位缓解持续时间13.5个月,中位无进展生存期3.5个月,中位总生存期7.9个月,安全性良好。
要点
- 帕博利珠单抗在经重度治疗的PD-L1阳性晚期前列腺癌中客观缓解率达17.4%。
- 中位缓解持续时间达13.5个月,显示持久应答。
- 治疗相关不良事件多数为1-2级,未发生治疗相关死亡或停药。
核心结论
- 帕博利珠单抗在经重度治疗、PD-L1阳性的晚期前列腺癌患者中产生持久客观缓解,且安全性良好。
研究设计与样本
- 非随机Ib期KEYNOTE-028试验的前列腺腺癌队列,纳入23例晚期前列腺腺癌患者。
- 患者接受帕博利珠单抗10 mg/kg每2周一次,直至疾病进展或不可耐受毒性,最长24个月。
- 主要终点为研究者按RECIST v1.1评估的客观缓解率。
主要发现
- 确证部分缓解4例,客观缓解率17.4%(95%CI 5.0%-38.8%)。
- 疾病稳定8例(34.8%),中位缓解持续时间13.5个月。
- 中位无进展生存期3.5个月,中位总生存期7.9个月;6个月无进展生存率和总生存率分别为34.8%和73.4%。
- 14例(60.9%)发生治疗相关不良事件,最常见为恶心(3例,13.0%)。
- 4例(17.3%)发生3/4级治疗相关不良事件:3级周围神经病变、3级乏力、3级疲劳和4级脂肪酶升高。
关键数值与推荐
- 入组标准包括晚期前列腺腺癌、标准治疗失败、按RECIST v1.1可测量病灶、PD-L1在≥1%的肿瘤或基质细胞中表达。
- 患者中位年龄65岁,73.9%接受过至少两种针对转移性疾病的既往治疗。
临床怎么用
- 对于经重度治疗且PD-L1阳性的晚期前列腺癌患者,帕博利珠单抗可作为可选治疗方案之一。
- 治疗期间需监测免疫相关不良事件,如周围神经病变、乏力和脂肪酶升高。
局限性
- 本研究为非随机Ib期小样本队列(n=23),结果需在更大规模研究中验证。
- 入组限于PD-L1阳性(≥1%)患者,结论不能外推至PD-L1阴性人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with castration-resistant prostate cancer derive only modest clinical benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) receptor by monoclonal antibodies has been effective in several malignancies. Results from the prostate adenocarcinoma cohort of the nonrandomized phase Ib KEYNOTE-028 trial of pembrolizumab in advanced solid tumors are presented. MATERIALS AND METHODS: Key eligibility criteria included advanced prostate adenocarcinoma, unsuccessful standard therapy, measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1), and PD-1 ligand (PD-L1) expression in ≥1% of tumor or stromal cells. Patients received pembrolizumab 10 mg/kg every 2 weeks until disease progression or intolerable toxicity for up to 24 months. Primary end point was objective response rate (ORR) per RECIST v1.1 by investigator review. RESULTS: Median patient age in this cohort (n = 23) was 65 years; 73.9% of patients received at least two prior therapies for metastatic disease. There were four confirmed partial responses, for an ORR of 17.4% [95% confidence interval (CI) 5.0%-38.8%]; 8 of 23 (34.8%) patients had stable disease. Median duration of response was 13.5 months. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 7.9 months, respectively; 6-month PFS and OS rates were 34.8% and 73.4%, respectively. One patient remained on treatment at data cutoff. After a median follow-up of 7.9 months, 14 (60.9%) patients experienced treatment-related adverse events (TRAEs), most commonly nausea (n = 3, 13.0%). Four (17.3%) experienced grade 3/4 TRAEs: grade 3 peripheral neuropathy, grade 3 asthenia, grade 3 fatigue, and grade 4 lipase increase. No pembrolizumab-related deaths or discontinuations occurred. CONCLUSION: Pembrolizumab resulted in durable objective response in a subset of patients with heavily pretreated, advanced PD-L1-positive prostate cancer, and its side effect profile was favorable. CLINICALTRIALS.GOV IDENTIFIER: NCT02054806.
引用
- Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018. PMID: 29992241. doi:10.1093/annonc/mdy232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。